Mycobacterium leprae: Pathogenesis, diagnosis, and treatment options.
Mungroo MR, Khan NA, Siddiqui R.
Microb Pathog. 2020 Dec;149:104475. doi: 10.1016/j.micpath.2020.104475. Epub 2020 Sep 12.
Treatment and Evaluation Advances in Leprosy Neuropathy.
Ebenezer GJ, Scollard DM.
Neurotherapeutics. 2021 Oct;18(4):2337-2350. doi: 10.1007/s13311-021-01153-z. Epub 2021 Nov 19.
Leprosy reactions: New knowledge on pathophysiology, diagnosis, treatment and prevention.
Mehta H, Jain S, Narang T, Chhabra S, Dogra S.
Indian J Dermatol Venereol Leprol. 2025 Jul-Aug;91(4):470-481. doi: 10.25259/IJDVL_915_2024.
Type 2 leprosy reaction resembling Sweet syndrome: Review of new and published cases.
Chavez-Alvarez S, Herz-Ruelas M, Ocampo-Candiani J, Gomez-Flores M.
Australas J Dermatol. 2020 May;61(2):e234-e237. doi: 10.1111/ajd.13224. Epub 2020 Jan 27.
Case Report: Type 2 Leprosy Reaction Mimicking Sweet Syndrome: A Case Report and Literature Review.
Bao C, Xu Q, Zou Y, Xiao Z, Cheng B, Gong T, Ji C.
Am J Trop Med Hyg. 2024 Feb 13;110(3):487-490. doi: 10.4269/ajtmh.23-0333. Print 2024 Mar 6.
Type 1 reaction in leprosy: a model for a better understanding of tissue immunity under an immunopathological condition.
Andrade PR, Pinheiro RO, Sales AM, Illarramendi X, Barbosa MG, Moraes MO, Jardim MR, Nery JA, Sampaio EP, Sarno EN.
Expert Rev Clin Immunol. 2015 Mar;11(3):391-407. doi: 10.1586/1744666X.2015.1012501. Epub 2015 Feb 10.
Type 1 reaction, neuritis and disability in leprosy. What is the current epidemiological situation?
Lienhardt C, Fine PE.
Lepr Rev. 1994 Mar;65(1):9-33. doi: 10.5935/0305-7518.19940002.
Leprous neuropathy.
de Freitas MR, Said G.
Handb Clin Neurol. 2013;115:499-514. doi: 10.1016/B978-0-444-52902-2.00028-X.
Lepromatous leprosy presenting with type II reaction before and type I reaction after treatment.
Robati RM, Mozafari N, Bidari-Zerehpoosh F, Niknejad N, Bizaval Z.
Dermatol Online J. 2020 Sep 15;26(9):13030/qt1f76n0b4.
Persistent Infection Versus Type 2 Immunological Reaction in Lepromatous Leprosy.
Tanabe MB, Group AR, Rincon L, Stryjewska BM, Sarria JC.
J Investig Med High Impact Case Rep. 2020 Jan-Dec;8:2324709620927884. doi: 10.1177/2324709620927884.
